News - North America, Merck & Co

Filter

Current filters:

North AmericaMerck & Co

Popular Filters

1 to 25 of 74 results

FDA advisory panel backing for Merck/ALK ragweed allergy immunotherapy Ragwitek

FDA advisory panel backing for Merck/ALK ragweed allergy immunotherapy Ragwitek

28-01-2014

The US Food and Drug Administration’s Allergenic Products Advisory Committee has voted that the available…

Alk-AbelloImmunologicalsMerck & CoNorth AmericaPharmaceuticalRagwitekRegulationUSA

FDA advisory panel votes to approve Merck & Co’s vorapaxar

FDA advisory panel votes to approve Merck & Co’s vorapaxar

16-01-2014

There was a positive outcome for US pharma giant Merck & Co yesterday, when a US Food and Drug Administration…

Cardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationUSAvorapaxarZontivity

Merck starts roll-out of BLA for MK-3475; vorapaxar FDA panel review

Merck starts roll-out of BLA for MK-3475; vorapaxar FDA panel review

14-01-2014

US drug giant Merck & Co says it has started a rolling submission to the US Food and Drug Administration…

Cardio-vascularMerck & CoMK-3475North AmericaOncologyPharmaceuticalRegulationUSAvorapaxarZontivity

Unanimous FDA panel support for Merck & Co’s Grastek

Unanimous FDA panel support for Merck & Co’s Grastek

13-12-2013

The Allergenic Products Advisory Committee (APAC) of the US Food and Drug Administration yesterday voted…

Alk-AbelloGrastekGrazaxImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulation

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development

10-12-2013

The development program for MK-8931, a novel investigational oral beta-amyloid precursor protein site-cleaving…

Anti-Arthritics/RheumaticsFinancialFosamaxMerck & CoMK-8931NeurologicalNorth AmericaPharmaceuticalResearch

Forest spends $240 million for US rights to Saphris; streamlines operations

02-12-2013

US drugmaker Forest Laboratories is acquiring exclusive rights in the USA for Saphris (asenapine) sublingual…

FinancialForest LaboratoriesLicensingMerck & CoNeurologicalNorth AmericaPharmaceuticalSaphrisUSA

Pharma figures high in EU R&D Investment Scoreboard, but led by US firms

19-11-2013

Though not topping the league table, the pharmaceutical industry had a number of drugmakers among the…

EuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck & CoNorth AmericaNovartisPfizerPharmaceuticalResearchRocheSanofi

Akorn shells out $52.8 million for rights to three Merck drugs

Akorn shells out $52.8 million for rights to three Merck drugs

18-11-2013

USA-based niche generic drugmaker Akorn has acquired from pharma giant Merck & Co the US rights to three…

AkornAzaSiteCosoptGenericsMerck & CoMergers & AcquisitionsNorth AmericaOphthalmics

New ACC and AHA guidelines could increase sales of statins

New ACC and AHA guidelines could increase sales of statins

13-11-2013

New clinical guidelines have been published for the treatment of cholesterol in people at high risk of…

AbbVieAstraZenecaCardio-vascularCrestorHealthcareLipitorMerck & CoNorth AmericaPfizerPharmaceuticalTricorUSAZetia

Merck’s investigational Timothy grass allergy tablet reduced symptoms in Phase III study

Merck’s investigational Timothy grass allergy tablet reduced symptoms in Phase III study

12-11-2013

US pharma giant Merck & Co (NYSE: MRK) has published positive results for its investigational Timothy…

ALK AbelloGrazaxImmunologicalsMerck & CoNorth AmericaPharmaceuticalResearchUSA

Merck & Co’s investigational HPV vaccine shows broader efficacy than Gardasil

Merck & Co’s investigational HPV vaccine shows broader efficacy than Gardasil

04-11-2013

Merck & Co has revealed an overview of its clinical trial program for V503, its investigational nine-valent…

GardasilMerck & CoNorth AmericaPharmaceuticalResearchVaccines

Merck & Co expects to file BLA for HPV vaccine candidate V503 this year

Merck & Co expects to file BLA for HPV vaccine candidate V503 this year

25-10-2013

Merck & Co yesterday provided an overview of the clinical trial program for V503, the company’s investigational…

Merck & CoNorth AmericaPharmaceuticalRegulationResearchV503Vaccines

FDA grants Merck’s hepatitis C treatment breakthrough designation

FDA grants Merck’s hepatitis C treatment breakthrough designation

23-10-2013

US pharma giant Merck & Co has announced that the US Food and Drug Administration has granted MK-5172/MK-8742…

Anti-viralsMerck & CoNorth AmericaPharmaceuticalRegulation

Avanir to promote Merck's diabetes drug Januvia

13-08-2013

US drugmaker Avanir Pharmaceuticals (Nasdaq: AVNR) has entered into an exclusive agreement with US drug…

Avanir PharmaceuticalsDiabetesJanuviaMarkets & MarketingMerck & CoNorth AmericaPharmaceutical

Generic Temodar launches in USA

13-08-2013

Israel-headquartered Teva Pharmaceutical Industries (NYSE: TEVA) and Perrigo (NYSE: PRGO;TASE) today…

GenericsMarkets & MarketingMerck & CoNorth AmericaOncologyPerrigoTemodarTeva Pharmaceutical Industries

Merck & Co records loss in 2nd quarter as Singulair drops 80%

30-07-2013

US pharma giant Merck & Co (NYSE: MRK) has released second quarter results showing that worldwide sales…

FinancialGardasilIsentressJanumetJanuviaMerck & CoNorth AmericaPharmaceuticalRemicadeSimponi ARIASingulairVytorinZetia

Slow uptake of HPV vaccine in USA "risks health of next generation"

29-07-2013

US human papillomavirus (HPV) vaccination rates in girls aged 13-17 years failed to increase between…

CervarixGardasilGlaxoSmithKlineHealthcareMerck & CoNorth AmericaPharmaceuticalVaccines

Merck & Co's NDA for vorapaxar accepted for standard review by US FDA

25-07-2013

US pharma giant Merck & Co (NYSE: MRK) has said the New Drug Application (NDA) for its once-troubled…

Cardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationvorapaxar

US FDA delays Merck & Co's insomnia drug suvorexant, issuing CRL

01-07-2013

There was disappointment for US drug giant Merck & Co (NYSE: MRK), which said that it has received a…

Merck & CoNeurologicalNorth AmericaPharmaceuticalRegulationsuvorexant

Intas Pharma settles with Roche over Xeloda; Merck & Co wins injunction against Aprica

25-06-2013

Indian drugmaker Intas Pharmaceuticals and its wholly owned subsidiary Accord Healthcare have entered…

Aprica PharmaceuticalsAsia-PacificDiabetesGenericsIntas PharmaceuticalsMerck & CoNorth AmericaOncologyPatentsRocheXeloda

InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against

17-06-2013

InSite Vision (OTC BB: INSV) that it will US pharma giants join Merck & CO (NYSE: MRK) and Pfizer (NYSE:…

AzaSiteGenericsInSite VisionLegalMerck & CoMylan LaboratoriesNorth AmericaOphthalmicsPatentsPfizerPharmaceutical

US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses

23-05-2013

The US Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee…

Merck & CoNeurologicalNorth AmericaPharmaceuticalRegulationsuvorexant

US FDA accepts Merck & Co's BLA ragweed pollen allergy immunotherapy

09-05-2013

US pharma giant Merck & Co (NYSE: MRK) revealed yesterday (May 8) that the Biologics License Application…

Alk-AbelloBiotechnologyImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulation

1 to 25 of 74 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top